ArticleiScience2025
PSMD8 cooperates with USP14 to promote bladder cancer progression by inhibiting ferroptosis.
Article in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ubiquitin-proteasome system (UPS) is crucial for regulating protein stability and essential cellular functions, including cell survival and proliferation. Dysregulation of UPS components contributes directly to malignant tumor development. This study investigates the significance of the proteasome subunit PSMD8 in bladder cancer (BLCA) pathogenesis. We found that elevated PSMD8 expression in BLCA specimens is strongly associated with a worse patient prognosis. Mechanistic studies demonstrated that PSMD8 promotes BLCA cell proliferation, migration, and carcinogenesis. PSMD8 negatively regulates ferroptosis, but not apoptosis, by directly interacting with and stabilizing SLC7A11, a known ferroptosis suppressor. Furthermore, we illustrate that ubiquitin-specific peptidase 14 (USP14) collaborates with PSMD8 to enhance SLC7A11 protein abundance. Reduction of PSMD8, SLC7A11, or USP14 sensitizes BLCA cells to cisplatin. Our findings demonstrate that the PSMD8/USP14 axis stabilizes SLC7A11 to suppress ferroptosis, promoting malignant growth, which suggests that targeting SLC7A11 or USP14 may significantly benefit BLCA patients with PSMD8 overexpression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.